PerkinElmer (PKI) Declares $0.07 Quarterly Dividend; 0.2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
PerkinElmer (PKI) PT Raised to $175 at Stifel Following EPS and BioLegend Deal
July 27, 2021 6:18 AM EDTStifel analyst Daniel Arias raised the price target on PerkinElmer (NYSE: PKI) to $175.00 (from $155.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, PKI announced another acquisition (the company's 7th announced since Horizon in Nov '20 - though by far the... More
PerkinElmer (PKI) Acquires BioLegend for $5.25B
July 26, 2021 6:30 AM EDTPerkinElmer (NYSE: PKI) announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments.
BioLegend provides its academic and biopharmaceutical customers with best-in-class antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing. The transaction will be the largest in PerkinElmers history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary... More
